Twenty-seven percent of patients with stubborn high blood pressure harbor elevated cortisol levels, a shocking rate that flips decades of medical teaching on its head and promises real answers for treatment failures.
Story Snapshot
- MOMENTUM study across 50 U.S. centers finds hypercortisolism in 27% of resistant hypertension cases, far exceeding prior estimates.
- Simple overnight dexamethasone test detects excess cortisol, the stress hormone driving unyielding blood pressure.
- Dr. Deepak L. Bhatt calls for immediate screening changes, challenging medical school doctrines.
- Findings could slash heart attack and heart failure risks for one-quarter of high-risk patients.
- Next steps include trials for cortisol-targeting therapies to finally tame resistant hypertension.
MOMENTUM Study Reveals Cortisol’s Hidden Role
The MOMENTUM study examined 1,086 patients with resistant hypertension across 50 nationwide centers. Researchers discovered hypercortisolism in 27% of cases. This condition features excess cortisol production, which medical education long dismissed as rare in such patients. Published March 30, 2026, the results demand physicians rethink standard approaches. Patients on three or more medications yet still hypertensive now have a testable culprit. This multi-center effort delivers robust evidence that cortisol silently sabotages blood pressure control.
Cortisol regulates stress responses as a glucocorticoid hormone. Chronic elevation triggers weight gain, muscle loss, diabetes, and cardiovascular strain. In resistant hypertension patients, already at high heart attack and heart failure risk, unchecked cortisol amplifies dangers. The study spotlights why medications fail: hormonal interference overrides drugs. Identifying this factor equips doctors to target root causes, not just symptoms.
Simple Test Unlocks Diagnosis
Physicians perform an overnight dexamethasone suppression test for screening. Patients ingest dexamethasone at bedtime, then provide a morning blood sample. Cortisol levels exceeding 1.8 ug/dL signal hypercortisolism. This accessible method fits routine practice without invasive procedures. Mount Sinai Health System joined 50 centers in validating its reliability. Results prompt swift action, potentially sparing patients fruitless medication trials. Early detection promises better outcomes through precise interventions.
Dr. Deepak L. Bhatt, MD, MPH, MBA, champions expanded protocols. He states the 27% rate starkly contradicts historical teachings. Doctors learned hypercortisolism rarely caused resistant hypertension, yet data proves otherwise. Bhatt urges systematic screening and randomized trials for cortisol therapies. His expertise as an established cardiologist bolsters the push for change. Patients, frustrated by failures, eagerly seek such explanations.
Immediate and Lasting Impacts Emerge
Short-term, cardiologists and primary care doctors gain awareness, spurring cortisol tests in resistant cases. Patients request evaluations after medication letdowns. Major centers adjust protocols. Long-term, new cortisol-reducing treatments develop, medical curricula revise, and blood pressure control improves for 27% of sufferers. Healthcare systems cut cardiovascular event costs. Pharmaceutical firms eye cortisol drugs. Endocrinology-cardiology teamwork grows, expanding diagnostics.
Resistant hypertension patients face steep heart risks. Treating hypercortisolism could avert crises in one-quarter of them. Researchers drive this paradigm shift against outdated practices. Clinicians adapt to deliver results. Facts support Dr. Bhatt’s assertive stance: ignore cortisol at patients’ peril. Trials will confirm if cortisol therapies deliver, but momentum builds for transformative care.
Sources:
ScienceDaily: This overlooked hormone could be why your blood pressure won’t drop
Ivanhoe: This overlooked hormone could be why your blood pressure won’t drop
